Prostate cancer (medically referred as prostatic carcinoma) is a type of cancer that is mostly found among men aged over 65 years. With unmet medical needs, companies worldwide are trying to develop advanced drugs and therapies that could treat or minimize prostate cancer.

Mustang Bio, Inc. is one such biotechnology company that is focused on innovating novel therapies for hematologic cancers, solid tumors and rare genetic diseases. The company has recently announced that City of Hope, a renowned treatment and cancer research center, has commenced the treatment of its first patients in Phase 1 clinical study of MB-105.

For the record, MB-105 is a prostate stem cell antigen (PSCA) CAR (chimeric antigen receptor) T platform for treating prostate cancer.

According to reliable sources, the clinical study is CAR-T's first trial for prostate cancer in the U.S. which can register up to 33 patients. The primary endpoints of the trial are to define the optimal dose and side effects of PSCA CAR T cells in treating people who suffer from PSCA-positive CRPC (castration-resistant prostate cancer).

Moreover, the secondary endpoints involve evaluating the persistence and expansion of PSCA CAR T cells, the clinical response based on Prostate Cancer Working Group 3 (PCWG3) criteria and establishing the PSCA expression level on tumor cells preceding to CAR T cell infusion.

Tanya Dorff, M.D., the trial’s principal investigator and associate clinical professor, City of Hope, commented that there is a long-lasting requirement of an effective therapy that would offer a much durable remission to patients with prostate cancer.

She further claims that CAR T cell therapy has successfully treated some cancers that were previously tough to treat, and this trial intends to show the same results with prostate cancer. Moreover, the company hopes that this cell therapy could significantly help patients suffering from prostate cancer.

Prior to the recent advancement, the City of Hope had obtained a grant of $9.28 million from the California Institute for Regenerative Medicine (CIRM) to finance its open-ended Phase 1 trial of MB-103 for the treatment of HER2-positive breast cancer with brain metastases.

Source Credit: http://ir.mustangbio.com/file/Index?KeyFile=399788338